DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL), 1,000 recall — FDA D-0434-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
April 2026 recalls — page 9
These records include useful source details for the selected month.
DrugApr 15, 2026
Fagron Compounding Services Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride recall — FDA D-0442-2026
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Class IIFDA: OngoingFagron Compounding Services
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 250 mL recall — FDA D-0431-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 50 mL x60, Becton, Dickson and Company recall — FDA D-0429-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP 0.9% (450 mg per 50 mL) (9 mg per mL) 50 recall — FDA D-0425-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 1,000 recall — FDA D-0433-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
DEXTROSE 5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL recall — FDA D-0436-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
DEXTROSE 5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 mL recall — FDA D-0437-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Clonidine Transdermal System, USP, 0.3 mg/day, supplied in cartons of 4 Systems and 4 recall — FDA D-0474-2026
CGMP Deviations: use of an unapproved raw material
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugApr 15, 2026
DEXTROSE 5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL recall — FDA D-0435-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only recall — FDA D-0423-2026
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
Class IIFDA: OngoingCipla USA, Inc.
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 100 mL recall — FDA D-0430-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Fagron Compounding Services Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride recall — FDA D-0440-2026
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Class IIFDA: OngoingFagron Compounding Services
DrugApr 15, 2026
Clonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 recall — FDA D-0472-2026
CGMP Deviations: use of an unapproved raw material
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, (4,500 mg per 500 mL) (9 mg per mL) 500 recall — FDA D-0428-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 0.9% (900 mg per 100 mL) (9 mg per mL) recall — FDA D-0426-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL) 500 mL recall — FDA D-0432-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Clonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 recall — FDA D-0473-2026
CGMP Deviations: use of an unapproved raw material
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugApr 15, 2026
SODIUM CHLORIDE 0.45% Sodium Chloride Injection, USP, 1.125 grams per 250 mL recall — FDA D-0424-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, (2,250 mg per 250 mL) (9 mg per mL) 250 recall — FDA D-0427-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingFresenius Kabi USA, LLC
DrugApr 15, 2026
Fagron Compounding Services Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride recall — FDA D-0441-2026
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Class IIFDA: OngoingFagron Compounding Services
VehicleApr 14, 2026
Ford engine block heater recall — NHTSA campaign 26V239000
Ford Motor Company (Ford) is recalling certain 2025 Maverick and 2026 Bronco Sport vehicles equipped with a 1.5L or 2.0L MPC engine and an engine block heater. The engine block heater may…
engine block heaterFord Motor Company
VehicleApr 14, 2026
Bronco automatic transmission recall — NHTSA campaign 26V236000
Ford Motor Company (Ford) is recalling certain 2021-2025 Bronco vehicles. The transmission to transfer case joint may be misaligned due to an incorrectly performed previous repair, which…
automatic transmissionFord Motor Company
VehicleApr 9, 2026
Jeep Wrangler vehicle tether anchor recall — NHTSA campaign 26V224000
Chrysler (FCA US, LLC) is recalling certain 2026 Jeep Wrangler vehicles. The child seat tether welds on the second-row, right-side seat frame may be insufficient, which can reduce the…
vehicle tether anchorChrysler (FCA US, LLC)
How to use this monthly recall archive
Use this page to compare the recalls reported during the month, then open an individual record for the exact reason, classification, company, remedy or distribution information available from the official source. Monthly counts are descriptive, not a safety rating.